Tenascin-N inhibitors are a specialized group of chemical compounds specifically designed to target and inhibit the function of Tenascin-N, a member of the tenascin family of extracellular matrix proteins. Tenascin-N is known for its involvement in various cellular processes, particularly those related to the structure and function of the extracellular matrix. The inhibitors in this class are characterized by their unique ability to interact with and modulate the activity of Tenascin-N, primarily through binding to specific sites on the protein. This interaction is crucial for the inhibitors' effectiveness, as it directly influences Tenascin-N's role in the extracellular matrix. The molecular structure of Tenascin-N inhibitors is typically complex and carefully designed to maximize binding affinity and specificity. These structures often include a variety of functional groups, which are strategically positioned to facilitate interactions with key domains of the Tenascin-N protein, such as those involved in binding to other extracellular matrix components or cell surface receptors.
The development of Tenascin-N inhibitors involves a combination of advanced chemical synthesis, molecular biology, and computational modeling techniques. Researchers in this field focus on understanding the precise molecular interactions between these inhibitors and Tenascin-N, employing a range of methodologies such as X-ray crystallography, NMR spectroscopy, and molecular docking studies. These techniques are pivotal in determining the optimal configuration of the inhibitors, ensuring that they effectively target Tenascin-N with high specificity. Furthermore, the physicochemical properties of Tenascin-N inhibitors, such as solubility, stability, and molecular weight, are critical considerations in their development. These properties are meticulously optimized to enhance the inhibitors' performance in terms of their interaction with Tenascin-N and their behavior in various environments. The intricate design of Tenascin-N inhibitors reflects the complexity of their target protein and the crucial role that precise molecular interactions play in achieving effective inhibition of Tenascin-N's function in the extracellular matrix.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine inhibits the Hedgehog signaling pathway, which may downregulate extracellular matrix protein genes like Tenascin-N. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a Notch pathway inhibitor that could potentially decrease Tenascin-N expression by altering cell differentiation signals. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin is known for its role in modulating various signaling pathways, which could include those regulating Tenascin-N transcription. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine affects lysosomal function and autophagy, which might impact cellular pathways and thereby reduce Tenascin-N expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid influences cell differentiation and may alter the expression of extracellular matrix components, including Tenascin-N. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin causes DNA damage which can influence transcriptional regulation, potentially decreasing Tenascin-N expression. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A 83-01 is an inhibitor of TGF-β type I receptor ALK5, which might downregulate Tenascin-N expression through altered signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib affects proteasome activity, potentially altering the stability of transcription factors regulating Tenascin-N expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor that can change the epigenetic state of genes, potentially affecting Tenascin-N expression. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY 364947 is a TGF-β receptor kinase inhibitor that might downregulate Tenascin-N expression by influencing TGF-β signaling. | ||||||